UROV News and Press, Urovant Sciences Ltd. From 03/28/19

By Bill Langbein, Founder SanaCurrents One of the strongest performing biopharmaceutical stocks this year is Evolus ( EOLS ). When the FDA on February 1 approved the company’s lead product Jeuveau, a potential Botox competitor, the stock shot up to about $25 per share. Since then ...

Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company developing and commercializing innovative therapies for urologic conditions, today announced that it has initiated COURAGE, an international Phase 3 trial to evaluate the safety and efficacy of vibegron for symptom...

Gainers:  Vaxart (NASDAQ: VXRT ) +108% . Sorrento Therapeutics (NASDAQ: SRNE ) +34% . Conformis (NASDAQ: CFMS ) +23% . Blucora (NASDAQ: BCOR ) +20% . StoneCo (NASDAQ: STNE ) +19% . Realm Therapeutics ( RLM ) +19% . Iterum Therapeutics (NASDAQ: ITRM ) +18% . Altimmune (NASDAQ: A...

AquaBounty Technologies (NASDAQ: AQB )  -21%  on equity offering . More news on: AquaBounty Technologies, Inc., Urovant Sciences Ltd., Daré Bioscience, Inc., Stocks on the move, Read more ...

Thinly traded micro cap Urovant Sciences (NASDAQ: UROV ) is up  9%  premarket on light volume on the heels of a positive outcome from a Phase 3 clinical trial, EMPOWUR , evaluating vibegron in adults with overactive bladder. More news on: Urovant Sciences Ltd., Healthcare stoc...

Vibegron met both co-primary endpoints demonstrating highly significant reduction in daily urge urinary incontinence episodes and micturitions, compared to placebo (p<0.0001 and p<0.001, respectively) Vibegron met all seven key secondary endpoints, including a clinically meani...

Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions, today announced it will host a conference call and live webcast to discuss topline results from the EMPOWUR international pivo...

Agilent (NYSE: A ) initiated with Buy rating and $92 (14% upside) price target at UBS. More news on: Agilent Technologies, Inc., Amgen Inc., Fluidigm Corporation, Healthcare stocks news, Stocks on the move, , Read more ...

This article is part of a series that provides an ongoing analysis of the changes made to Ole Andreas Halvorsen’s 13F stock portfolio on a quarterly basis. It is based on Viking Global’s regulatory 13F Form filed on 02/14/2019. Please visit our Tracking Ole Andreas Halvorsen&#...

Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing novel therapies for urologic conditions, today announced Chief Executive Officer Keith A. Katkin is scheduled to present a corporate overview at the Cowen and Company 39 th Annual Healthcare ...